Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 11/06/25
Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology TranscriptSeeking Alpha • 10/31/25
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common StockPRNewsWire • 10/31/25
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science JournalPRNewsWire • 10/30/25
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study UpdatePRNewsWire • 09/10/25
Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferencePRNewsWire • 09/02/25
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementPRNewsWire • 08/12/25
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 08/07/25
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025PRNewsWire • 08/04/25
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)PRNewsWire • 06/30/25
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 StudyPRNewsWire • 06/11/25
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingPRNewsWire • 05/29/25
Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the HorizonPRNewsWire • 05/28/25
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 05/13/25
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in FrancePRNewsWire • 05/06/25
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate UpdatePRNewsWire • 03/13/25
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic ReviewPRNewsWire • 01/28/25
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6PRNewsWire • 01/10/25
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)PRNewsWire • 12/12/24
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private PlacementPRNewsWire • 11/21/24
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)PRNewsWire • 11/18/24